Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
60%
Ph early_phase_1
1
20%
Ph phase_2
1
20%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 33 (60.0%)

Trials by Status

completed120%
recruiting120%
not_yet_recruiting120%
unknown240%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruitingphase_3

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

NCT07752784
recruitingphase_3

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

NCT07422857
completedphase_3

[18F]APN-1607 PET in Subjects With AD Compared to HC

NCT05542953
unknownearly_phase_1

Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients

NCT05043675
unknownphase_2

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT04141150

Clinical Trials (5)

Showing 5 of 5 trials
NCT07752784Phase 3

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

Not Yet Recruiting
NCT07422857Phase 3

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Recruiting
NCT05542953Phase 3

[18F]APN-1607 PET in Subjects With AD Compared to HC

Completed
NCT05043675Early Phase 1

Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients

Unknown
NCT04141150Phase 2

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5